|
Demographic information and pathological characteristics of study participants and distribution of characteristics |
|
| n (%) |
|
|
|
|
| Age at diagnosis |
|
| ≤50 years |
133 (46) |
| >50 years |
158 (54) |
| Race |
|
| Caucasian |
239 (82) |
| African-American |
52 (18) |
| Stage and node status |
|
| Stage 1 |
82 (28) |
| Stage 2 negative |
57 (20) |
| Stage 2 positive |
87 (30) |
| Stage 3 |
48 (16) |
| Stage 4 |
17 (6) |
| Estrogen receptor status |
|
| Positive |
176 (64) |
| Negative |
101 (36) |
| Progesterone receptor status |
|
| Positive |
128 (46) |
| Negative |
148 (54) |
| Treatment |
|
| Chemotherapy only |
95 (33) |
| Radiation only |
25 (9) |
| Chemotherapy/radiation |
54 (19) |
| radiation/tamoxifen |
36 (12) |
| Chemotherapy/tamoxifen |
44 (16) |
| Chemotherapy/radiation/tamoxifen |
35 (12) |
|
Total n = 291. | |
Martin et al. Breast Cancer Research 2006 8:R45 doi:10.1186/bcr1532 |
|